These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38490920)

  • 1. Association between CFTR modulators and changes in iron deficiency markers in cystic fibrosis.
    Jia S; Wang Y; Ross MH; Zuckerman JB; Murray S; Han MK; Cahalan SE; Lenhan BE; Best RN; Taylor-Cousar JL; Simon RH; Fitzgerald LJ; Troost JP; Sood SL; Gifford AH
    J Cyst Fibros; 2024 Sep; 23(5):878-884. PubMed ID: 38490920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Search of Optimal Criteria for Iron Deficiency in CHF Patients. Post-hoc Analysis of the Study "Prevalence of Iron Deficiency in Patients With Chronic Heart Failure in the Russian Federation (ID-CHF-RF)".
    Mareev VY; Mareev YV; Kobalava ZD; Begrambekova YL; Karapetyan LV; Galochkin SA; Kazakhmedov ER; Lapshin AA; Garganeeva AA; Kuzheleva EA; Efremushkina AA; Kiseleva EV; Barbarash OL; Pecherina TB; Galyavich AS; Galeeva ZM; Baleeva LV; Koziolova NA; Veclich AS; Duplyakov DV; Maksimova MN; Yakushin SS; Smirnova EA; Sedykh EV; Shaposhnik II; Makarova NA; Zemlyanukhina AA; Skibitsky VV; Fendrikova AV; Skibitsky AV; Spiropoulos NA; Seredenina EM; Orlova YA; Eruslanova KA; Kotovskaya YV; Tkacheva ON; Fedin MA
    Kardiologiia; 2024 Sep; 64(9):16-27. PubMed ID: 39392265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly effective cystic fibrosis transmembrane conductance (regulator) modulator therapy: shifting the curve for most while leaving some further behind.
    Chun SW; Somers ME; Burgener EB
    Curr Opin Pediatr; 2024 Jun; 36(3):290-295. PubMed ID: 38411576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CFTR Modulator Use Is Associated with Higher Hemoglobin Levels in Individuals with Cystic Fibrosis.
    Gifford AH; Heltshe SL; Goss CH
    Ann Am Thorac Soc; 2019 Mar; 16(3):331-340. PubMed ID: 30580531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cystic Fibrosis Transmembrane Conductance Regulator Modulator Use Is Associated With Reduced Pancreatitis Hospitalizations in Patients With Cystic Fibrosis.
    Ramsey ML; Gokun Y; Sobotka LA; Wellner MR; Porter K; Kirkby SE; Li SS; Papachristou GI; Krishna SG; Stanich PP; Hart PA; Conwell DL; Lara LF
    Am J Gastroenterol; 2021 Dec; 116(12):2446-2454. PubMed ID: 34665155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pregnancy among cystic fibrosis women in the era of CFTR modulators.
    Heltshe SL; Godfrey EM; Josephy T; Aitken ML; Taylor-Cousar JL
    J Cyst Fibros; 2017 Nov; 16(6):687-694. PubMed ID: 28190780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges in the use of highly effective modulator treatment for cystic fibrosis.
    Ramos KJ; Pilewski JM; Taylor-Cousar JL
    J Cyst Fibros; 2021 May; 20(3):381-387. PubMed ID: 33531206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneity of CFTR modulator-induced sweat chloride concentrations in people with cystic fibrosis.
    Zemanick ET; Emerman I; McCreary M; Mayer-Hamblett N; Warden MN; Odem-Davis K; VanDevanter DR; Ren CL; Young J; Konstan MW;
    J Cyst Fibros; 2024 Jul; 23(4):676-684. PubMed ID: 38360461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of Highly Effective Modulator Therapy on Cystic Fibrosis Microbiology and Inflammation.
    Caverly LJ; Riquelme SA; Hisert KB
    Clin Chest Med; 2022 Dec; 43(4):647-665. PubMed ID: 36344072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Skilton M; Krishan A; Patel S; Sinha IP; Southern KW
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009841. PubMed ID: 30616300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pseudomonas aeruginosa infection, but not mono or dual-combination CFTR modulator therapy affects circulating regulatory T cells in an adult population with cystic fibrosis.
    Westhölter D; Beckert H; Straßburg S; Welsner M; Sutharsan S; Taube C; Reuter S
    J Cyst Fibros; 2021 Nov; 20(6):1072-1079. PubMed ID: 34030985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
    Ong T; Ramsey BW
    Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and Risk Factors for Iron Deficiency in Adults With Cystic Fibrosis.
    Gettle LS; Harden A; Bridges M; Albon D
    Nutr Clin Pract; 2020 Dec; 35(6):1101-1109. PubMed ID: 31994790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study.
    Zemanick ET; Konstan MW; VanDevanter DR; Rowe SM; Clancy JP; Odem-Davis K; Skalland M; Mayer-Hamblett N
    J Cyst Fibros; 2021 Nov; 20(6):965-971. PubMed ID: 33573995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient personalized translational tools in cystic fibrosis to transform data from bench to bed-side and back.
    Arora K; Yang F; Brewington J; McPhail G; Cortez AR; Sundaram N; Ramananda Y; Ogden H; Helmrath M; Clancy JP; Naren AP
    Am J Physiol Gastrointest Liver Physiol; 2021 Jun; 320(6):G1123-G1130. PubMed ID: 33949881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of CFTR modulator therapy on cystic fibrosis-related diabetes.
    Gaines H; Jones KR; Lim J; Medhi NF; Chen S; Scofield RH
    J Diabetes Complications; 2021 Jun; 35(6):107845. PubMed ID: 33558149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis.
    Merlo CA; Thorat T; DerSarkissian M; McGarry LJ; Nguyen C; Gu YM; Healy J; Rubin JL; Brookhart MA
    Thorax; 2024 Sep; 79(10):925-933. PubMed ID: 38937105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical, economic, and societal burden of cystic fibrosis and the impact of the CFTR modulator, lumacaftor/ivacaftor: an assessment using linked registry data in Sweden.
    Lindblad A; Monestrol I; Gilljam M; Krantz C; McGarry LJ; Banefelt J; Aldvén M
    J Med Econ; 2024; 27(1):897-906. PubMed ID: 38939921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries.
    Volkova N; Moy K; Evans J; Campbell D; Tian S; Simard C; Higgins M; Konstan MW; Sawicki GS; Elbert A; Charman SC; Marshall BC; Bilton D
    J Cyst Fibros; 2020 Jan; 19(1):68-79. PubMed ID: 31196670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis.
    Burgener EB; Moss RB
    Curr Opin Pediatr; 2018 Jun; 30(3):372-377. PubMed ID: 29538046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.